Amol Akhade/LinkedIn
Apr 16, 2025, 08:15
Amol Akhade: Comparison of Sacituzumab Govitecan and Sacituzumab Tirumotecan in mTNBC
Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:
“And then There were TWO.
Nice summary slide to Compare Sacituzumab govitecan-hziy and Sacituzumab tirumotecan in advanced TNBC based upon recently published data of Later in Nature.
Do note The difference in structure and efficacy of both ADCs.
More posts featuring mTNBC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 10:02
Jun 8, 2025, 09:53
Jun 8, 2025, 09:53
Jun 8, 2025, 09:31
Jun 8, 2025, 09:15